James Luke Godwin

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano et al. · Journal of Clinical Oncology · 2020 · 292 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

James Luke Godwin, Shuchie Jaggi, Imali Sirisena et al. · Journal for ImmunoTherapy of Cancer · 2017 · 128 citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

Joaquim Bellmunt, Andrea Necchi, Ronald de Wit et al. · Journal of Clinical Oncology · 2021 · 55 citations

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar et al. · European Urology Oncology · 2020 · 52 citations · Full text

Medicine, Oncology, Pharmacology +13

Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

J.A. Marascio, Daniel E. Spratt, Jingbin Zhang et al. · Prostate Cancer and Prostatic Diseases · 2019 · 43 citations · Full text

Medicine, Oncology, Urology +17